Bailard’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$984K Sell
12,288
-143
-1% -$11.8K 0.02% 326
2025
Q4
$1.06M Buy
12,431
+1,406
+13% +$115K 0.02% 312
2025
Q3
$857K Buy
11,025
+2,625
+31% +$205K 0.02% 355
2025
Q2
$657K Sell
8,400
-256
-3% -$19.1K 0.02% 422
2025
Q1
$627K Buy
8,656
+660
+8% +$47.2K 0.02% 413
2024
Q4
$592K Sell
7,996
-31,187
-80% -$2.18M 0.02% 428
2024
Q3
$2.59M Sell
39,183
-16,043
-29% -$1.17M 0.07% 205
2024
Q2
$5.1M Sell
55,226
-530
-1% -$46.9K 0.14% 136
2024
Q1
$5.33M Buy
55,756
+6,343
+13% +$533K 0.15% 138
2023
Q4
$3.77M Sell
49,413
-7,218
-13% -$502K 0.11% 163
2023
Q3
$3.92M Buy
56,631
+789
+1% +$63.4K 0.13% 141
2023
Q2
$5.27M Sell
55,842
-12,750
-19% -$1.11M 0.18% 109
2023
Q1
$5.67M Sell
68,592
-360
-0.5% -$28.3K 0.2% 107
2022
Q4
$5.14M Sell
68,952
-1,215
-2% -$93.6K 0.2% 106
2022
Q3
$5.8M Buy
70,167
+682
+1% +$65.6K 0.24% 95
2022
Q2
$6.61M Buy
69,485
+288
+0.4% +$29.8K 0.26% 85
2022
Q1
$8.15M Buy
69,197
+2,855
+4% +$320K 0.27% 85
2021
Q4
$8.6M Sell
66,342
-2,166
-3% -$253K 0.27% 85
2021
Q3
$7.76M Sell
68,508
-294
-0.4% -$33.6K 0.27% 90
2021
Q2
$7.13M Sell
68,802
-77
-0.1% -$7.26K 0.25% 95
2021
Q1
$5.76M Buy
+68,879
New +$5.82M 0.21% 102
2020
Q3
Sell
-2,944
Closed -$203K 584
2020
Q2
$203K Buy
+2,944
New +$209K 0.01% 435
2019
Q4
Sell
-2,901
Closed -$213K 559
2019
Q3
$213K Buy
+2,901
New +$204K 0.01% 462

Other funds holding EW

Bailard's EW Position: Q1 2026 in Review

Bailard reduced its Edwards Lifesciences (EW) stake by 1.2% in Q1 2026, selling an estimated $11.8K and leaving 12,288 shares worth $984K. The position accounts for 0.02% of the portfolio, ranked #326.

Bailard first reported a position in EW in Q3 2019 and has held it in 23 quarters since. The position peaked at $8.6M in Q4 2021. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Bailard held 12,288 shares of Edwards Lifesciences worth $984K as of Q1 2026.
  • Bailard sold 143 Edwards Lifesciences shares in Q1 2026, an estimated $11.8K.
  • Edwards Lifesciences made up 0.02% of Bailard's portfolio in Q1 2026, its #326 holding.
  • Bailard first reported a position in Edwards Lifesciences in Q3 2019 and has held it in 23 quarters since.
  • Bailard's Edwards Lifesciences position peaked at $8.6M in Q4 2021.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Bailard's 13F filing for Q1 2026, filed 11 May 2026.